Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Return on Capital Employed (2020 - 2025)

Addex Therapeutics' Return on Capital Employed history spans 6 years, with the latest figure at 48.2% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 99.0% to 48.2% in Q4 2025 year-over-year; TTM through Dec 2025 was 48.2%, a 99.0% decrease, with the full-year FY2025 number at 40.0%, up 34.0% from a year prior.
  • Return on Capital Employed came in at 48.2% for Q4 2025, up from 67.57% in the prior quarter.
  • The five-year high for Return on Capital Employed was 586.3% in Q1 2024, with the low at 695.9% in Q1 2023.
  • Historically, Return on Capital Employed has averaged 172.64% across 5 years, with a median of 127.66% in 2021.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 128220bps in 2024 and later crashed -64057bps in 2025.
  • Year by year, Return on Capital Employed stood at 165.78% in 2021, then plummeted by -227bps to 542.49% in 2022, then surged by 73bps to 148.97% in 2023, then soared by 68bps to 47.21% in 2024, then decreased by -2bps to 48.2% in 2025.
  • Business Quant data shows Return on Capital Employed for ADXN at 48.2% in Q4 2025, 67.57% in Q3 2025, and 60.1% in Q2 2025.